<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40681395</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0938</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Cardiovascular revascularization medicine : including molecular interventions</Title><ISOAbbreviation>Cardiovasc Revasc Med</ISOAbbreviation></Journal><ArticleTitle>Comparative efficacy and safety of latest generation ultrathin and thin biodegradable polymer vs. durable polymer drug-eluting stents in small vessel coronary artery disease: A systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1553-8389(25)00356-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.carrev.2025.07.004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Biodegradable polymer drug-eluting stents (BP-DES) are a well-established treatment for coronary artery disease. However, the long-term efficacy and safety of BP-DES versus durable polymer drug-eluting stents (DP-DES) in patients with small vessel coronary artery disease (SVCAD) remains uncertain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched PubMed, Embase, and Cochrane Central databases for randomized controlled trials (RCTs) comparing BP-DES versus DP-DES in patients with SVCAD in November 2024. We applied a random-effects model to pool risk ratios (RR) with their 95&#xa0;% confidence intervals (CIs). All statistical analyses were performed using R software 4.3.1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed data from RCTs including 7072 patients for TLF at 1&#xa0;year, with SVCAD undergoing percutaneous coronary intervention (PCI), of whom 4026 (56.9&#xa0;%) received BP-DES. Compared to DP-DES, BP-DES were associated with a significantly lower rate of target lesion failure at 2&#xa0;years (RR 0.81, 95&#xa0;% CI: 0.67-0.98, p&#xa0;=&#xa0;0.03) and target vessel myocardial infarction at 1&#xa0;year (RR: 0.61, 95&#xa0;% CI: 0.43-0.87, p&#xa0;=&#xa0;0.006). However, no significant differences in target lesion failure were observed at 1 and 5&#xa0;years, nor in stent thrombosis. Furthermore, the individual components of TLF-target lesion revascularization, and cardiac death-showed no significant differences between both stent types.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with small vessel coronary artery disease, BP-DES were associated with lower target lesion failure at 2&#xa0;years and reduced target vessel myocardial infarction at 1&#xa0;year compared to DP-DES; however, the 2-year TLF benefit was not maintained at 5&#xa0;years.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaramillo</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Facultad Ciencias Biom&#xe9;dicas, Universidad Austral, Buenos Aires, Argentina. Electronic address: sebastianjaramro@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Pontes</LastName><ForeName>Vinicius Bittar</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Centro Universit&#xe1;rio das Faculdades Associadas de Ensino, S&#xe3;o Jo&#xe3;o da Boa Vista, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinilla</LastName><ForeName>Juan Alejandro</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>CES University, School of Medicine, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stabile</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felix</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Federal University of Campina Grande, Campina Grande, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemente</LastName><ForeName>Mariana R C</ForeName><Initials>MRC</Initials><AffiliationInfo><Affiliation>Petropolis Medical School, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garot</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut Cardiovasculaire Paris Sud (ICPS), H&#xf4;pital Jacques Cartier, Ramsay-Sant&#xe9;, Massy, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Revasc Med</MedlineTA><NlmUniqueID>101238551</NlmUniqueID><ISSNLinking>1878-0938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biodegradable</Keyword><Keyword MajorTopicYN="N">Drug-eluting stents</Keyword><Keyword MajorTopicYN="N">Durable</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Small vessels</Keyword><Keyword MajorTopicYN="N">Thin</Keyword><Keyword MajorTopicYN="N">Ultrathin</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. PG reports being consultant for Abbott and Boston Scientific, and receiving speakers' fees from Abbott, Biosensors, Boston Scientific, Cordis, General Electric HealthCare, and Terumo. He is shareholder and serves as medical director of Cardiovascular European Research Center (CERC), a CRO dedicated to cardiovascular diseases.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>19</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>19</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>21</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40681395</ArticleId><ArticleId IdType="doi">10.1016/j.carrev.2025.07.004</ArticleId><ArticleId IdType="pii">S1553-8389(25)00356-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>